Alopecia areata in children

Childhood alopecia areata can severely affect quality of life and data are lacking regarding the use of methotrexate in this group of patients

These researchers therefore investigated the safety and efficacy of methotrexate in children with severe alopecia areata. This retrospective study included 14 children aged eight to 18 years who had alopecia areata for a mean duration of 5.7 years. The children received treatment once a week at a mean dose of 18.9mg for a mean duration of 14.2 months. Methotrexate treatment was considered successful in five of the 13 children who were assessed; the remainder were regarded as treatment failures. Methotrexate could cautiously be considered for severe alopecia areata, although further studies are needed to prove its efficacy.
Royer M, Bodemer C, Vabres P et al. Br J Dermatol 2011; 165: 407-10

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more